Jing Zhao

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 683 citations · Full text

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 505 citations · Full text

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler et al. · Clinical Infectious Diseases · 2010 · 204 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +16

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Peter Schmid, Javier Cortés, Rebecca Dent et al. · Annals of Oncology · 2019 · 80 citations · Full text

Pembro Vs Pbo, Breast Oncology, Oncology +8

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Tejal Patel, Joe Ensor, Sarah L. Creamer et al. · Breast Cancer Research · 2019 · 65 citations · Full text